This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Objective To assess the utility of dose frequency adjustment of tocilizumab (TCZ) in rheumatoid arthritis (RA).
Methods Patients who received TCZ at 3-week (n = 24) or 5-week (n = 61) interval were evaluated.
Results Disease Activity Score at 28 joints based on erythrocyte sedimentation rate in the 3-week group significantly improved after 3 administrations at 3-week intervals (from 4.2 to 2.7, p = 0.001). Forty-five of the patients in the 5-week group (74%) successfully continued 5-week interval administration without disease exacerbation. Lower C-reactive protein level at TCZ initiation and shorter duration to remission achievement were key to successful dose frequency reduction.
Conclusion Adjusting the dose frequency of intravenous TCZ is a useful strategy.